http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107929282-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365 |
| filingDate | 2017-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107929282-B |
| titleOfInvention | Medicinal use of ginkgolide composition |
| abstract | The invention provides the application of the ginkgolide composition in preparing a medicine for preventing/treating frontotemporal dementia. It has been proved by experiments that the ginkgolide composition dose-dependently inhibits the vitality of peripheral blood lymphocytes in patients with frontotemporal dementia, and inhibits the phosphorylation of TDP-43 protein in lymphocytes, thereby promoting activation by inhibiting the phosphorylation of TDP-3 protein. The translocation of TDP-43 protein from the cytoplasm to the nucleus reduces the accumulation of TDP-43 protein in the cytoplasm and inhibits cell proliferation by reducing the expression of CDK6 protein in lymphocytes. At the same time, the experiment also proved that the ginkgolide composition dose-dependently inhibited the proliferation of human neuroblastoma cells damaged by EA-induced injury, inhibited the phosphorylation of TDP-43 protein in cells and decreased the expression of CDK6 protein in cells. Therefore, the ginkgolide composition has the function and application value of being prepared as a medicine for relieving frontotemporal dementia. |
| priorityDate | 2017-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 86.